With the conclusion of the transition period under the EU Medical Device Regulation (MDR, Regulation (EU) 2017/745), the legislation has now entered its full enforcement phase. Under this regulatory upgrade, dental prosthetic materials are explicitly classified as Class IIa medical devices, meaning that all such products intended for the EU market must hold a valid MDR-CE certificate issued by an accredited Notified Body in order to be legally placed on the market.

I. Regulatory Background: A Historic Leap from MDD to MDR

The EU Medical Device Regulation (MDR) was officially published in May 2017, replacing the Medical Device Directive (MDD, 93/42/EEC) that had been in force for nearly three decades. Compared with the old directive, the MDR significantly tightens requirements across device classification rules, clinical evidence, post-market surveillance, Unique Device Identification (UDI), and the rigor of Notified Body assessments.

Following years of transitional arrangements, the MDR has now entered a phase of full mandatory enforcement. Products previously relying on MDD certificate "continuation" or "grace period" provisions must complete their MDR compliance conversion within the prescribed deadlines, or face removal from the EU market.

II. Dental Prosthetic Materials: What the Class IIa Classification Means

Under the classification rules set out in Annex VIII of the MDR, dental prosthetic materials - including but not limited to zirconia blocks, glass ceramics (such as Emax), resin temporary crown materials, flexible denture materials, implant abutments, and related prosthetic components - fall under Class IIa medical devices.

This classification carries the following implications:

Mandatory Notified Body assessment: Unlike Class I devices (which may be self-declared), Class IIa products require a conformity assessment carried out by an EU-accredited Notified Body. Manufacturers cannot self-declare compliance.

Significantly higher clinical evidence requirements: Manufacturers must provide robust clinical evidence, including clinical data, literature evaluations, or clinical investigations, to demonstrate product safety and performance.

Technical Documentation subject to Notified Body review: Documentation must cover product design, risk management (ISO 14971), biocompatibility (ISO 10993), sterilization validation, labeling, and instructions for use.

Post-Market Surveillance (PMS) and Periodic Safety Update Reports (PSUR) become legal obligations.

III. Notified Body MDR-CE Certification: The "Passport" to the EU Market

Under the MDR framework, a Notified Body is a third-party conformity assessment body designated by an EU Member State and accredited by the European Commission. Only CE certificates issued by Notified Bodies holding valid MDR designation are recognized by EU market surveillance authorities.

The industry currently faces several practical challenges:

Scarce Notified Body capacity: The number of Notified Bodies with MDR designation and dental-sector auditing experience is limited, and waiting lists are普遍 lengthy - in some cases extending several months to over a year.

Stricter assessment standards: Notified Body audits under the MDR are far deeper and broader than under the MDD. Insufficient clinical evidence, inadequate risk management, or missing technical documentation can all result in a failed assessment.

Certificate conversion pressure: Products holding legacy MDD certificates must undergo MDR re-certification within the transition window. Those that fail to convert in time will lose their right to remain on the EU market.

IV. Impact and Response for Dental Manufacturers

For dental OEM/ODM manufacturers that rely on the EU as a key export market, the full enforcement of the MDR has far-reaching consequences:

Dramatically higher market access barriers: Without a valid MDR-CE certificate, products cannot enter the 27 EU Member States, nor can they clear customs through the European Economic Area (EEA).

Significantly rising compliance costs: Notified Body assessment fees, clinical evaluations, technical documentation preparation, and quality management system upgrades (ISO 13485) all require substantial financial and human resources.

Accelerating supply chain consolidation: Small and medium-sized enterprises may exit the EU market due to unaffordable compliance costs, while industry resources concentrate among leading players with full compliance capabilities.

Enhanced brand trust: Companies holding MDR-CE certification will gain greater trust from European dentists and distribution partners, making the certification a powerful differentiator in competitive positioning.

Industry experts recommend that relevant companies launch MDR compliance projects as early as possible, prioritize Notified Bodies with proven dental-sector experience, establish robust quality management systems, and treat clinical evaluation and technical documentation preparation as core strategic priorities.

V. Conclusion

The full enforcement of the EU MDR marks the beginning of a new era in global medical device regulation - one defined by stricter oversight and a patient-safety-first approach. As Class IIa medical devices, dental prosthetic materials no longer have the option of treating MDR-CE certification as a discretionary step; it has become a mandatory precondition for EU market access. For dental manufacturers deeply engaged in the European market, proactively embracing compliance and advancing certification ahead of schedule is not only essential to retaining market share, but also the key to securing a competitive advantage in the coming industry reshuffle.